PMID- 27269937
OWN - NLM
STAT- MEDLINE
DCOM- 20170724
LR  - 20240313
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 34
IP  - 26
DP  - 2016 Sep 10
TI  - Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death 
      Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial 
      Bladder Cancer.
PG  - 3119-25
LID - 10.1200/JCO.2016.67.9761 [doi]
AB  - PURPOSE: To investigate the safety and efficacy of durvalumab, a human monoclonal 
      antibody that binds programmed cell death ligand-1 (PD-L1), and the role of PD-L1 
      expression on clinical response in patients with advanced urothelial bladder 
      cancer (UBC). METHODS: A phase 1/2 multicenter, open-label study is being 
      conducted in patients with inoperable or metastatic solid tumors. We report here 
      the results from the UBC expansion cohort. Durvalumab (MEDI4736, 10 mg/kg every 2 
      weeks) was administered intravenously for up to 12 months. The primary end point 
      was safety, and objective response rate (ORR, confirmed) was a key secondary end 
      point. An exploratory analysis of pretreatment tumor biopsies led to defining 
      PD-L1-positive as >/= 25% of tumor cells or tumor-infiltrating immune cells 
      expressing membrane PD-L1. RESULTS: A total of 61 patients (40 PD-L1-positive, 21 
      PD-L1-negative), 93.4% of whom received one or more prior therapies for advanced 
      disease, were treated (median duration of follow-up, 4.3 months). The most common 
      treatment-related adverse events (AEs) of any grade were fatigue (13.1%), 
      diarrhea (9.8%), and decreased appetite (8.2%). Grade 3 treatment-related AEs 
      occurred in three patients (4.9%); there were no treatment-related grade 4 or 5 
      AEs. One treatment-related AE (acute kidney injury) resulted in treatment 
      discontinuation. The ORR was 31.0% (95% CI, 17.6 to 47.1) in 42 
      response-evaluable patients, 46.4% (95% CI, 27.5 to 66.1) in the PD-L1-positive 
      subgroup, and 0% (95% CI, 0.0 to 23.2) in the PD-L1-negative subgroup. Responses 
      are ongoing in 12 of 13 responding patients, with median duration of response not 
      yet reached (range, 4.1+ to 49.3+ weeks). CONCLUSION: Durvalumab demonstrated a 
      manageable safety profile and evidence of meaningful clinical activity in 
      PD-L1-positive patients with UBC, many of whom were heavily pretreated.
CI  - (c) 2016 by American Society of Clinical Oncology.
FAU - Massard, Christophe
AU  - Massard C
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Gordon, Michael S
AU  - Gordon MS
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Sharma, Sunil
AU  - Sharma S
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Rafii, Saeed
AU  - Rafii S
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Wainberg, Zev A
AU  - Wainberg ZA
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Luke, Jason
AU  - Luke J
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Curiel, Tyler J
AU  - Curiel TJ
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Colon-Otero, Gerardo
AU  - Colon-Otero G
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Hamid, Omid
AU  - Hamid O
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Sanborn, Rachel E
AU  - Sanborn RE
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - O'Donnell, Peter H
AU  - O'Donnell PH
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Drakaki, Alexandra
AU  - Drakaki A
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Tan, Winston
AU  - Tan W
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Kurland, John F
AU  - Kurland JF
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Rebelatto, Marlon C
AU  - Rebelatto MC
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Jin, Xiaoping
AU  - Jin X
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Blake-Haskins, John A
AU  - Blake-Haskins JA
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Gupta, Ashok
AU  - Gupta A
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Segal, Neil H
AU  - Segal NH
AD  - Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; 
      Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, 
      Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research 
      Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of 
      California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research 
      Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of 
      Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University 
      of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston 
      Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, 
      Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. 
      Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, 
      Memorial Sloan Kettering Cancer Center, New York, NY. segaln@mskcc.org.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20160606
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (durvalumab)
SB  - IM
CIN - J Clin Oncol. 2016 Sep 10;34(26):3115-6. PMID: 27458310
CIN - J Urol. 2018 Feb;199(2):341-342. PMID: 29357560
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - B7-H1 Antigen/*antagonists & inhibitors/metabolism
MH  - Biopsy
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Middle Aged
MH  - Time Factors
MH  - Treatment Outcome
MH  - Urinary Bladder Neoplasms/*drug therapy/metabolism/mortality/pathology
MH  - Urothelium/*drug effects/metabolism/pathology
PMC - PMC5569690
COIS- Authors' disclosures of potential conflicts of interest are found in the article 
      online at www.jco.org. Author contributions are found at the end of this article.
EDAT- 2016/06/09 06:00
MHDA- 2017/07/25 06:00
PMCR- 2016/10/10
CRDT- 2016/06/09 06:00
PHST- 2016/06/09 06:00 [entrez]
PHST- 2016/06/09 06:00 [pubmed]
PHST- 2017/07/25 06:00 [medline]
PHST- 2016/10/10 00:00 [pmc-release]
AID - JCO.2016.67.9761 [pii]
AID - 679761 [pii]
AID - 10.1200/JCO.2016.67.9761 [doi]
PST - ppublish
SO  - J Clin Oncol. 2016 Sep 10;34(26):3119-25. doi: 10.1200/JCO.2016.67.9761. Epub 
      2016 Jun 6.